Compare Incyte Corporation (INCY) vs Upstart Holdings Inc (UPST) Price & Performance

Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.

The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.

Upstart Holdings trades at $24.19, up 0.71% with bearish technical signals despite recent partnership expansions. The company achieved profitability in 2025 with $1.02B revenue and $53.6M net income, though recent quarters show earnings misses. Valuation ratios remain elevated with P/E of 46.52 and P/S of 2.1, while analyst consensus targets $39.50 with mixed sentiment.

The stock faces near-term pressure from technical weakness and earnings volatility, but long-term potential exists through AI-driven lending expansion and new auto/HELOC partnerships. Key risks include credit market sensitivity, rising debt levels, and competitive fintech landscape. Current price near recent lows presents opportunity for patient investors despite operational cash flow challenges.